import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "vasopressin-avp-neuropeptide-research-guide",
  title: "Vasopressin (AVP): Neuropeptide Research Guide",
  description:
    "A comprehensive research overview of arginine vasopressin (AVP) — covering receptor pharmacology, central and peripheral mechanisms, social behavior and stress axis research, memory consolidation studies, and protocol considerations for preclinical investigations.",
  category: "Compound Profiles",
  readMinutes: 11,
  publishedAt: "2026-06-04",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Arginine vasopressin (AVP), also designated antidiuretic hormone (ADH), is a cyclic nonapeptide synthesized predominantly in the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei. While its peripheral role in renal water reabsorption has been well-characterized for decades, the breadth of AVP's central nervous system functions — spanning social cognition, stress axis modulation, memory consolidation, and affiliative behavior — has made it a significant target in contemporary neuropeptide research. This guide summarizes the mechanisms, receptor pharmacology, and preclinical research landscape relevant to laboratory investigations involving AVP.",
    },
    {
      type: "callout",
      text: "Vasopressin and related analogs referenced in this article are discussed in the context of preclinical research. All research compounds are for laboratory investigation only and are not intended for human administration, therapeutic use, or clinical application outside approved medical contexts.",
    },
    {
      type: "heading",
      text: "Molecular Biology and Receptor Pharmacology",
    },
    {
      type: "paragraph",
      text: "AVP is a nine-amino-acid cyclic peptide with a disulfide bridge between cysteine residues at positions 1 and 6 (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂). This cyclic structure is essential for receptor binding and confers resistance to some but not all peptidases in the circulation. The closely related neuropeptide oxytocin differs from AVP at only two amino acid positions (positions 3 and 8), and this structural similarity is reflected in partial cross-reactivity between AVP and oxytocin receptors — a relevant consideration for experimental specificity.",
    },
    {
      type: "subheading",
      text: "Receptor Subtypes",
    },
    {
      type: "list",
      items: [
        "V1aR (AVPR1A): Expressed widely in brain regions including the lateral septum, amygdala, bed nucleus of the stria terminalis, and hypothalamus. Primary mediator of AVP's central social behavior effects. Also expressed in vascular smooth muscle (peripheral vasoconstriction). G protein-coupled; activates Gq/phospholipase C pathway.",
        "V1bR (AVPR1B): Expressed in the anterior pituitary and limbic structures, particularly the hippocampus. Mediates AVP-driven ACTH release from corticotroph cells — a key link between AVP and HPA axis stress responses. Gq-coupled.",
        "V2R (AVPR2): Expressed predominantly in renal collecting duct cells. Mediates antidiuretic effects via Gs-cAMP-PKA signaling leading to aquaporin-2 (AQP2) trafficking. Not a primary target for central neuropeptide research but highly relevant in fluid homeostasis and vasopressin analog pharmacology.",
        "OTR cross-reactivity: At supraphysiological concentrations, AVP binds oxytocin receptors and vice versa. Experimental designs requiring receptor-specific attribution should incorporate selective antagonists (e.g., SR49059 for V1aR, SSR149415 for V1bR) to control for cross-reactivity.",
      ],
    },
    {
      type: "heading",
      text: "Social Behavior and Affiliative Research",
    },
    {
      type: "paragraph",
      text: "The most intensively studied CNS function of AVP in preclinical models is its role in social recognition, social memory, and pair bonding — particularly through V1aR-mediated signaling in the lateral septum and ventral forebrain.",
    },
    {
      type: "subheading",
      text: "Social Memory and Recognition",
    },
    {
      type: "paragraph",
      text: "AVP in the lateral septum has been consistently linked to social memory formation in rodent models. Lim et al. and subsequent replication studies demonstrated that central AVP infusion enhances social recognition performance, while V1aR antagonism impairs it. The mechanism involves hippocampal-septal projections modulating the consolidation of olfactory social cues — the primary modality through which rodents identify conspecifics.",
    },
    {
      type: "subheading",
      text: "Pair Bonding: Prairie Vole Research",
    },
    {
      type: "paragraph",
      text: "The prairie vole (Microtus ochrogaster) has been an invaluable model for AVP-mediated pair bonding research. Prairie voles express substantially higher V1aR density in the ventral pallidum compared to non-monogamous meadow voles — a receptor distribution difference that Young et al. demonstrated could be transferred pharmacologically: intracerebral V1aR agonist delivery to meadow voles partially recapitulated partner preference behavior. These findings generated significant research interest in AVP receptor system contributions to affiliative behavior across mammalian species.",
    },
    {
      type: "subheading",
      text: "Implications for Autism Spectrum Disorder Research",
    },
    {
      type: "paragraph",
      text: "Deficits in social cognition and recognition represent core features of autism spectrum disorder (ASD). Preclinical research has investigated whether AVP system modulation can ameliorate social deficits in ASD rodent models (CNTNAP2 knockout, SHANK3 mutant mice). Parker et al. (2017) reported that intranasal vasopressin improved social motivation in children in a pilot clinical study — work that catalyzed ongoing research into intranasal AVP as a translational intervention candidate. This literature is active and evolving, and preclinical protocol designs targeting social deficits in genetic ASD models remain a productive research area.",
    },
    {
      type: "heading",
      text: "HPA Axis and Stress Research",
    },
    {
      type: "paragraph",
      text: "AVP is a co-regulator of the hypothalamic-pituitary-adrenal (HPA) axis. In the PVN, AVP is co-expressed with corticotropin-releasing hormone (CRH) in parvocellular neurons projecting to the median eminence. Both CRH and AVP are released into the portal circulation to stimulate ACTH secretion from anterior pituitary corticotrophs — with AVP acting via V1bR and potentiating CRH-driven ACTH release rather than serving as an independent first signal.",
    },
    {
      type: "paragraph",
      text: "In chronic stress models, the ratio of AVP to CRH co-expression in PVN parvocellular neurons shifts in favor of AVP — a finding replicated across species and stress modalities. This shift has been proposed as a mechanism by which chronic stress sensitizes the HPA axis: AVP is more resistant to glucocorticoid negative feedback than CRH, potentially contributing to the HPA hyperreactivity and feedback impairment associated with chronic stress exposure and major depressive disorder.",
    },
    {
      type: "subheading",
      text: "V1bR Antagonism Research",
    },
    {
      type: "paragraph",
      text: "The V1bR selective antagonist SSR149415 has been extensively used in preclinical stress and depression models. Studies using SSR149415 report anxiolytic and antidepressant-like effects in forced swim, tail suspension, and social defeat models — consistent with the hypothesis that V1bR-driven HPA overactivation contributes to stress-related affective pathology. These findings have informed clinical development of V1bR antagonists, though no agents have reached approval for psychiatric indications as of 2026.",
    },
    {
      type: "heading",
      text: "Memory and Cognitive Function",
    },
    {
      type: "paragraph",
      text: "AVP has been studied as a modulator of memory consolidation and retrieval since the 1970s, when de Wied demonstrated that systemic or central AVP administration enhanced passive avoidance retention in rats. The mechanism was attributed to central AVP effects rather than peripheral — a conclusion supported by the activity of des-glycinamide AVP, a metabolite without peripheral antidiuretic activity that retains memory-enhancing properties in animal models.",
    },
    {
      type: "paragraph",
      text: "More recent research has examined AVP in the context of hippocampal-dependent spatial memory and contextual fear conditioning. V1aR expression in the hippocampus and entorhinal cortex positions AVP as a modulator of encoding and consolidation processes, with some studies reporting V1aR agonism enhances consolidation while V1aR antagonism impairs it in spatial tasks. The interaction between AVP signaling and hippocampal NMDA receptor function is an active research focus.",
    },
    {
      type: "heading",
      text: "Intranasal Administration in Research",
    },
    {
      type: "paragraph",
      text: "Intranasal peptide delivery has become a standard research administration route for neuropeptides including AVP and oxytocin, largely because it provides a non-invasive route for CNS delivery in human translational studies. The mechanism of CNS entry via the intranasal route remains a subject of active investigation — olfactory and trigeminal nerve pathways have been proposed as direct perivascular conduits bypassing the blood-brain barrier, though systemic absorption with subsequent CNS penetration remains a competing explanation.",
    },
    {
      type: "subheading",
      text: "Intranasal Protocol Considerations",
    },
    {
      type: "list",
      items: [
        "Vehicle: Sterile saline is standard. Buffer pH should be ≈7.4 to minimize mucosal irritation and maintain peptide stability.",
        "Concentration and volume: Rodent intranasal delivery typically uses 1–5 µL per naris to avoid overflow into the trachea. Human translational studies have used 20 IU (approximately 40 µg) doses.",
        "Timing relative to behavioral testing: CNS effects of intranasally delivered AVP are typically observed within 30–60 minutes of administration in rodent models; peak CNS concentrations vary by study and delivery method.",
        "Controls: Vehicle-only controls are essential. Cross-reactivity with oxytocin receptors should be controlled with receptor-selective antagonists when attributing effects to AVP pathways specifically.",
        "Sex differences: AVP system density and behavioral responsiveness show documented sex differences in rodent models — V1aR expression patterns differ between males and females in social behavior-relevant regions. Include sex as a biological variable or confine studies to one sex with explicit justification.",
      ],
    },
    {
      type: "heading",
      text: "Peripheral Roles Relevant to Research Design",
    },
    {
      type: "paragraph",
      text: "Researchers focused on AVP's central functions should nonetheless account for peripheral actions when designing protocols, as these can confound behavioral and physiological endpoints:",
    },
    {
      type: "list",
      items: [
        "Renal antidiuresis (V2R): AVP reduces urine output and increases urine osmolality. In studies with fluid intake endpoints or when body weight is a controlled variable, AVP-driven antidiuresis can introduce confounds.",
        "Vascular tone (V1aR, peripheral): AVP is a potent vasoconstrictor at pharmacological doses, increasing mean arterial pressure. Studies using supra-physiological AVP doses must account for cardiovascular effects as a potential confounder.",
        "Platelet aggregation (V1aR): AVP promotes platelet aggregation via V1aR. Studies in bleeding or thrombosis models should note this action.",
        "Liver glycogenolysis (V1aR): AVP stimulates hepatic glycogenolysis. In metabolic studies, this peripheral action may influence glucose endpoints.",
      ],
    },
    {
      type: "heading",
      text: "Research Models and Endpoints",
    },
    {
      type: "table",
      headers: ["Research Domain", "Common Models", "Key Endpoints"],
      rows: [
        ["Social memory", "Rodent social recognition paradigm, CNTNAP2 KO, SHANK3 mutant", "Discrimination ratio, investigation time, preference index"],
        ["Pair bonding", "Prairie vole partner preference test", "Partner preference score, huddling time"],
        ["HPA stress axis", "Chronic variable stress, social defeat, forced swim", "ACTH levels, corticosterone, CRH/AVP PVN co-expression"],
        ["Memory consolidation", "Passive avoidance, Morris water maze, contextual fear conditioning", "Retention latency, escape latency, freezing %"],
        ["Depression/anxiety", "FST, TST, EPM, open field, sucrose preference", "Immobility, sucrose consumption, EPM time in open arms"],
        ["Fluid homeostasis", "Water deprivation, SIADH models", "Urine output, osmolality, serum sodium"],
      ],
    },
    {
      type: "heading",
      text: "Stability and Storage for Research Use",
    },
    {
      type: "paragraph",
      text: "Vasopressin in lyophilized form is stable at -20°C for extended periods. Reconstituted AVP solutions should be prepared in sterile physiological saline and used within 24 hours of reconstitution, or aliquoted and stored at -80°C for up to 30 days depending on concentration and study timeline. Repeated freeze-thaw cycles degrade peptide integrity; single-use aliquots are the recommended practice for experimental consistency.",
    },
    {
      type: "paragraph",
      text: "Researchers sourcing AVP for preclinical investigations should verify compound identity and purity via mass spectrometry and HPLC documentation. The disulfide bridge in AVP is essential for receptor binding — oxidative degradation (conversion to the open-chain form) renders the peptide pharmacologically inactive, and this degradation is not visible to the naked eye. COA confirmation of purity and identity at the lot level being used in the study is the standard practice.",
    },
    {
      type: "heading",
      text: "Current Research Directions",
    },
    {
      type: "paragraph",
      text: "Active areas of AVP research in 2026 include translational investigations in ASD and social cognition deficits, V1bR antagonist clinical development for treatment-resistant depression and stress-related disorders, the interaction between AVP signaling and GLP-1 receptor agonists in hypothalamic satiety circuits, and the role of AVP in mediating the social reward components of psychedelic-assisted therapy models.",
    },
    {
      type: "paragraph",
      text: "The neuropeptide field increasingly recognizes that AVP and oxytocin do not operate as independent systems but as a coordinated neuropeptide network — with evidence for heterodimer interactions at the receptor level, shared downstream signaling, and region-specific competition for receptor occupancy. Research designs that treat either peptide in isolation may underestimate the network-level complexity of the social behavior neural circuitry they are investigating.",
    },
    {
      type: "disclaimer",
      text: "Vasopressin and its analogs are discussed here in the context of preclinical laboratory research only. This content does not constitute medical advice and is not intended to guide clinical or therapeutic use. Researchers are responsible for compliance with all institutional, local, and federal regulations governing peptide research, including IACUC approval for animal studies.",
    },
  ],
};
